Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Jointown Pharmaceutical Group Co., Ltd.
  6. Summary
    600998   CNE100000W45

JOINTOWN PHARMACEUTICAL GROUP CO., LTD.

(600998)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
10/21/2021 10/22/2021 10/25/2021 10/26/2021 10/27/2021 Date
16.39 16.28 16.03 14.69 14.1 Last
8755598 4197702 5139443 20267490 14123620 Volume
+2.76% -0.67% -1.54% -8.36% -4.02% Change
Estimated financial data (e)
Sales 2021 127 B 19 871 M 19 871 M
Net income 2021 2 615 M 409 M 409 M
Net Debt 2021 3 923 M 613 M 613 M
P/E ratio 2021 10,1x
Yield 2021 3,90%
Sales 2022 152 B 23 770 M 23 770 M
Net income 2022 3 213 M 502 M 502 M
Net Debt 2022 9 687 M 1 514 M 1 514 M
P/E ratio 2022 8,21x
Yield 2022 4,08%
Capitalization 24 962 M 3 905 M 3 902 M
EV / Sales 2021 0,23x
EV / Sales 2022 0,23x
Nbr of Employees 28 213
Free-Float 34,3%
More Financials
Company
Jointown Pharmaceutical Group Co., Ltd. is principally engaged in the wholesaling and retailing of pharmaceuticals and medical equipments. The Company is also engaged in the research, development and production of drugs, as well as the provision of relevant value-added services. The CompanyÔÇÖs products mainly include western medicines, proprietary Chinese medicines, Chinese medicine pieces, Chinese herbal... 
Sector
Drug Retailers
Calendar
04/26Earnings Release
More about the company
Ratings of Jointown Pharmaceutical Group Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about JOINTOWN PHARMACEUTICAL GROUP CO., LTD.
10/25Jointown Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months En..
CI
08/24Jointown Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ende..
CI
04/26Jointown Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter ..
CI
03/16Tranche Update on Jointown Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announc..
CI
03/12Jointown Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on September 16, 202..
CI
02/25JOINTOWN PHARMACEUTICAL : Swiss Logistics Firm Kuehne+Nagel Partners with Jointown to Mana..
MT
02/24KUEHNE + NAGEL INTERNATIONAL : Kühne + Nagel International Signs Logistics Deal With China..
MT
01/22JOINTOWN PHARMACEUTICAL : ADB, Jointown Sign EUR30 Million Loan to Expand Pharmaceutical D..
AQ
01/21Sinovac COVID-19 vaccine unit struggles to add new hires as holiday nears
RE
01/05Tranche Update on Jointown Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announc..
CI
2020Jointown Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months En..
CI
2020China Cinda Asset Management Co., Ltd. cancelled the acquisition of 5.3% stake in Joint..
CI
2020Jointown Pharmaceutical Group Co., Ltd. Announces Completion of Cashing Phase V Ultra-S..
CI
2020Jointown Pharmaceutical Group Co., Ltd. announces an Equity Buyback for CNY 600 million..
CI
2020Jointown Pharmaceutical Group Co., Ltd. authorizes a Buyback Plan.
CI
More news
News in other languages on JOINTOWN PHARMACEUTICAL GROUP CO., LTD.

- No features available -

More news
Chart JOINTOWN PHARMACEUTICAL GROUP CO., LTD.
Duration : Period :
Jointown Pharmaceutical Group Co., Ltd. Technical Analysis Chart | 600998 | CNE100000W45 | MarketScreener
Technical analysis trends JOINTOWN PHARMACEUTICAL GROUP CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 14,10 CNY
Average target price 17,00 CNY
Spread / Average Target 20,6%
EPS Revisions
Managers and Directors
Yi Chang Liu General Manager & Director
Ying Zheng Xu Chief Financial & Accounting Officer
Xu Min Wen Chairman-Supervisory Board
Chang Yun Liu Chairman
Qi Ming Chen Director & Deputy General Manager-Investment
Sector and Competitors